Lymphocyte Therapy (CRH-treated PBMCs)

Repeated implantation failure (RIF) is one of the major problems in IVF / ICSI cycles. Despite many advances in infertility treatments, a significant percentage of couples who undergo in vitro fertilization treatment fail to conceive.

Embryo’s implantation and development occurs during a specific period known as the window of implantation. It has been suggested that the mother’s immune cells, especially the natural killer cells, play an important role in implantation. Application of CRH-treated PBMCs, can increase pregnancy rate in patients with recurrent IVF failure.

In this method, before embryo transfer, blood sample is obtained from patients. Then mononuclear cells (lymphocyte and monocyte) are prepared and cultured for 2 or 3 days. Intrauterine infusion of PBMC is perform 2 days before embryo transfer.

In fact, treatment of peripheral blood mononuclear cells with Corticotrophin-releasing hormone (CRH) during embryo implantation can improve the maternal – fetal immune system tolerance and thus increases pregnancy in RIF patients.